optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-6-yl piperazine-1-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinazolin-7-yl piperazine-1-carboxylate, or any one of the compounds represented by Formula 1, or any one of other novel compounds described herein, or a pharmaceutically acceptable salt thereof, (referred to collectively herein as a "subject compound") in the manufacture of a medicament for the treatment of cancer, infectious diseases, and other disorders associated with kinases.

[005a] In one aspect, the present disclosure refers to a compound represented by a formula:



or a pharmaceutically acceptable salt thereof;

wherein Ring A is:



or

, wherein the structure is optionally substituted with 1, 2, 3, 4, or 5 substituents and each substituent is independently F, Cl, Br, I, -NR^AR^B, C_{1-6} hydrocarbyl, -OH, -CN, or -O-C_{1-6} alkyl; wherein Y is N or CH; and wherein the asterisk indicates the point of attachment of C atom to L;

Ring B is 6-membered arylene that is optionally substituted with 1, 2, 3, or 4 substituents and each substituent is independently F, Cl, Br, I, -NR^AR^B, C_{1-6} hydrocarbyl, -OH, -CN, or -O-C_{1-6} alkyl;

Ring D is 3-membered carbocycle that is optionally substituted with 1, 2, 3, or 4 substituents and each substituent is independently F, Cl, Br, $-NR^AR^B$, C_{1-6} hydrocarbyl, -OH, -CN, or $-O-C_{1-6}$ alkyl;

L is -O-;

X is -O-, or $-N(R^B)-$;

R^A and R^B are independently H or C_{1-6} hydrocarbyl;

R^3 and R^4 are H;

R^1 and R^2 are independently H, C_{1-12} alkyl, C_{6-10} aryl, C_{3-9} heteroaryl, or C_{3-6} cycloalkyl, wherein R^1 and R^2, together with the N atom to which they are attached, may form a cyclic ring, a bicyclic ring, or a bridged cyclic ring system; and when X is $-N(R^B)-$, R^1 and R^B may be linked, and together with the N atom to which R^1 is attached and the carbonyl group to which X is attached, may form a cyclic ring, and wherein R^1 and R^2 are independently optionally substituted and each substituent is independently F, Cl, Br, I, $-NR^AR^B$, C_{1-6} hydrocarbyl, -OH, -CN, or $-O-C_{1-6}$ alkyl; and

R^5 is an optionally substituted phenyl with 1, 2, 3, 4, or 5 substituents and each substituent is independently F, Cl, Br, I, $-NR^AR^B$, C_{1-6} hydrocarbyl, -OH, -CN, or $-O-C_{1-6}$ alkyl.

[006] Some examples include a compound represented by Formula 1:



or a pharmaceutically acceptable salt thereof; wherein Ring A is an optionally substituted 10-membered heteroarylene having at least one ring nitrogen atom; Ring B is an optionally substituted 6-membered arylene or an optionally substituted 6-membered heteroarylene containing at least one ring nitrogen atom; Ring D is an optionally substituted 3, 4, 5, or 6-membered carbocycle or an optionally substituted 3, 4, 5, or 6-membered heterocycle; L is -O-, $-N(R^A)-$, or $-S(O)_{0-2}-$; X is -O-, or $-N(R^B)-$; R^A, R^B and R^3 are independently H or C_{1-6} hydrocarbyl; R^1 and R^2 are independently H, optionally substituted C_{1-12} alkyl, optionally substituted C_{6-10} aryl, optionally substituted C_{3-9} heteroaryl, or optionally substituted C_{3-6}

cycloalkyl, wherein R^1 and R^2, together with the N atom to which they are attached, may form an optionally substituted cyclic ring, an optionally substituted bicyclic ring, or an optionally substituted bridged cyclic ring system; and when X is -N(R^B)-, R^1 and R^B may be linked, and together with the N atom to which R^1 is attached and the carbonyl group to which X is attached, may form an optionally substituted cyclic ring; and R^4 and R^5 are independently H, an optionally substituted C_{1-12} hydrocarbyl, an optionally substituted C_{3-9} heteroaryl, or an optionally substituted C_{3-12} heterocycloalkyl, wherein R^4 and R^5, together with the nitrogen atom to which they are attached, may form an optionally substituted 4, 5, 6, or 7-membered heterocyclyl.

[006a] In another aspect, the present disclosure refers to compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:


,


,


,


,



,



,



,



,



,



,



,



,



,



,



,



,



,


,

,

,

,

,


,

,

,

,

,


,


,


,


,


,


,

,

,

,

,



,



,



,



, or



.

[007] Some examples include use of a compound described herein, such as a compound of Formula 1, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl piperazine-1-carboxylate, optionally substituted 4-(4-(1-

(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl piperidine-1-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl pyrrolidine-1-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl carbamate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl 2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl morpholine-4-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl (1R,4R)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate, or optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate, or a pharmaceutically acceptable salt thereof, (referred to collectively herein as a “subject compound”) in the manufacture of a medicament for the treatment of cancer, infectious diseases and other disorders associated with kinases.

[007a] In yet another aspect, the present disclosure refers to use of a compound as disclosed herein in the manufacture of a medicament for treating a kinase-mediated disease or disorder, wherein the use comprise that the compound is to be administered to a mammal in need thereof.

[008] Some examples include a pharmaceutical composition, a dosage form, and/or a medicament comprising a therapeutically effective amount of a subject compound in combination with at least one pharmaceutically acceptable carrier, referred to herein as a subject pharmaceutical composition. A subject pharmaceutical composition can optionally contain additional excipients.

[008a] In yet another aspect, the present disclosure refers to a pharmaceutical composition comprising a therapeutically effective amount of a compound as disclosed herein in combination with at least one pharmaceutically acceptable carrier.

[009] Some examples include a product kit comprising a subject pharmaceutical composition, optionally in the form of a dosage form, and a label describing how to administer the subject pharmaceutical composition to a mammal or a human being for the treatment of cancer, an infectious disease, or another disorder associated with a kinase.

[010] Some examples include a process for making a pharmaceutical composition comprising combining a subject compound and at least one pharmaceutically acceptable carrier.

DETAILED DESCRIPTION

[011] Unless otherwise indicated, any reference to a compound herein by structure, name, or any other means, includes pharmaceutically acceptable salts, such as sodium, potassium, and ammonium salts; prodrugs, such as ester prodrugs; alternate solid forms, such as

What is claimed is:

1. A compound represented by a formula:



or a pharmaceutically acceptable salt thereof;

wherein Ring A is:



or



, wherein the structure is optionally substituted with 1, 2, 3, 4, or 5 substituents and each substituent is independently F, Cl, Br, I, $-NR^AR^B$, C_{1-6} hydrocarbyl, -OH, -CN, or $-O-C_{1-6}$ alkyl; wherein Y is N or CH; and wherein the asterisk indicates the point of attachment of C atom to L;

Ring B is 6-membered arylene that is optionally substituted with 1, 2, 3, or 4 substituents and each substituent is independently F, Cl, Br, I, $-NR^AR^B$, C_{1-6} hydrocarbyl, -OH, -CN, or $-O-C_{1-6}$ alkyl;

Ring D is 3-membered carbocycle that is optionally substituted with 1, 2, 3, or 4 substituents and each substituent is independently F, Cl, Br, $-NR^AR^B$, C_{1-6} hydrocarbyl, -OH, -CN, or $-O-C_{1-6}$ alkyl;

L is -O-;

X is -O-, or $-N(R^B)-$;

R^A and R^B are independently H or C_{1-6} hydrocarbyl;

R^3 and R^4 are H;

R^1 and R^2 are independently H, C_{1-12} alkyl, C_{6-10} aryl, C_{3-9} heteroaryl, or C_{3-6} cycloalkyl, wherein R^1 and R^2, together with the N atom to which they are attached, may form a cyclic ring, a bicyclic ring, or a bridged cyclic ring system; and when X is -N(R^B)-, R^1 and R^B may be linked, and together with the N atom to which R^1 is attached and the carbonyl group to which X is attached, may form a cyclic ring, and wherein R^1 and R^2 are independently optionally substituted and each substituent is independently F, Cl, Br, I, -NR^AR^B, C_{1-6} hydrocarbyl, -OH, -CN, or -O-C_{1-6} alkyl; and

R^5 is an optionally substituted phenyl with 1, 2, 3, 4, or 5 substituents and each substituent is independently F, Cl, Br, I, -NR^AR^B, C_{1-6} hydrocarbyl, -OH, -CN, or -O-C_{1-6} alkyl.

2. The compound of claim 1, further represented by formula I or II:



(I)



(II)

or a pharmaceutically acceptable salt thereof, wherein each structure is independently optionally substituted and each substituent is independently F, Cl, Br, I, -NR^AR^B, C_{1-6} hydrocarbyl, -OH, -CN, or -O-C_{1-6} alkyl;

R^9 is -O-C_{1-6} alkyl; and

each R^{12} is H, F, Cl, C_{1-3} hydrocarbyl.

3. The compound of claim 2, wherein R^9 is -O-C_{1-3} alkyl.

4. The compound of claim 2, wherein R^9 is methoxy.

5. The compound of claim 2, 3, or 4, wherein Y is CH.

6. The compound of claim 2, 3, or 4, wherein Y is N.

7. The compound of claim 2, 3, 4, 5, or 6, wherein R^{12} is F.

8. The compound of claim 2, 3, 4, 5, or 6, wherein R^{12} is H.

9. The compound of claim 1, wherein -N(R^1)(R^2) is optionally substituted (R)-2,4-dimethylpiperazin-1-yl.

10. The compound of claim 1, wherein -N(R^1)(R^2) is optionally substituted (S)-2,4-dimethylpiperazin-1-yl.

11. The compound of claim 1, wherein -N(R^1)(R^2) is optionally substituted 4-methylpiperazin-1-yl.

12. The compound of claim 1, wherein -N(R^1)(R^2) is optionally substituted (R)-2-methylpiperazin-1-yl.

13. The compound of claim 1, wherein -N(R^1)(R^2) is optionally substituted 2-oxoimidazolidin-1-yl.

14. The compound of claim 1, wherein R^5 is unsubstituted phenyl.

15. The compound of claim 1, wherein R^5 is 4-fluorophenyl.

16. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl piperazine-1-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl piperidine-1-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl pyrrolidine-1-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl carbamate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl 2,6-dihydropyrrolo[3,4-c]pyrazole-5(4H)-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl morpholine-4-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl (1R,4R)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate, optionally substituted N-(4-((7-(2-oxoimidazolidin-1-

yl)quinolin-4-yl)oxy)phenyl)-N-phenylcyclopropane-1,1-dicarboxamide, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-6-yl piperazine-1-carboxylate, optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinazolin-7-yl piperazine-1-carboxylate, or optionally substituted 4-(4-(1-(phenylcarbamoyl)cyclopropane-1-carboxamido)phenoxy)quinolin-7-yl (1R,5S)-3,6-diazabicyclo[3.1.1]heptane-6-carboxylate.

17. A compound, or a pharmaceutically acceptable salt thereof, wherein the compound is:



,



,



,



,



,



,



,



,



,



,



,


H
N
O
O
H
N
F
O
O
N
O
HO
N

,


H
N
O
O
H
N
F
O
O
N
O
HO
N

,


H
N
O
O
H
N
F
O
O
N
O
N
N

,


H
N
O
O
H
N
F
O
O
N
O
N
N

,


,

,

,

,

,



,



,



,



,



,



,



,



,



,



,



,



,



,



,



,


,

,

,

,

,



, or



.

18. Use of a compound of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 in the manufacture of a medicament for treating a kinase-mediated disease or disorder, wherein the use comprise that the compound is to be administered to a mammal in need thereof.

19. The use of claim 18, wherein the disease is a kinase-mediated cancer.

20. The use of claim 18, wherein the disease is a kinase-mediated infectious disease.

21. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, or 17 in combination with at least one pharmaceutically acceptable carrier.